Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia

Overview of attention for article published in Frontiers in oncology, December 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 7 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 6,544 followers.

New research: Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia: The PI3K/Akt pathway—and in particular PI3Kδ—is known for its role in drug resistant B-cell acute lymphoblastic… https://t.

01 Dec 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.